Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS). The ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at ...

AI French-American biotech start-up Owkin recently published new research in the European Journal of Cancer that shows how AI can predict the survival of cancer patients by looking at clinical data ...